Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Marsh

Showing results (651-660 of 654) with videos related to

Pageof 66
Sort By:
You have reached the last page of results.This site can display upto 654 results.
CNS Neuroscience & Therapeutics|May 17, 2008
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing propertiesKarin R Tietje, David J Anderson, R Scott Bitner, et al.
Nature Medicine|January 8, 2013
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J Souers, Joel D Leverson, Erwin R Boghaert, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2018
UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of MalariaChristel Brunschwig, Nina Lawrence, Dale Taylor, et al.
Science Translational Medicine|April 28, 2017
Antimalarial efficacy of MMV390048, an inhibitor of <i>Plasmodium</i> phosphatidylinositol 4-kinaseTanya Paquet, Claire Le Manach, Diego González Cabrera, et al.
Pageof 66

Showing results (651-660 of 654) with videos related to

Sort By:
Pageof 66
You have reached the last page of results.This site can display upto 654 results.
CNS Neuroscience & Therapeutics|May 17, 2008
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing propertiesKarin R Tietje, David J Anderson, R Scott Bitner, et al.
Nature Medicine|January 8, 2013
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J Souers, Joel D Leverson, Erwin R Boghaert, et al.
Antimicrobial Agents and Chemotherapy|June 27, 2018
UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of MalariaChristel Brunschwig, Nina Lawrence, Dale Taylor, et al.
Science Translational Medicine|April 28, 2017
Antimalarial efficacy of MMV390048, an inhibitor of <i>Plasmodium</i> phosphatidylinositol 4-kinaseTanya Paquet, Claire Le Manach, Diego González Cabrera, et al.
Pageof 66